Clinical trial results In phase 3 trials, average weight loss over 68 weeks was: 20.4% with CagriSema 14.9% with semaglutide alone 11.5% with cagrilintide alone 3% with placebo Side effects were mostly mild to moderate, similar to current GLP-1s
Moreover, the ability of PQQ to protect against neurodegeneration may go beyond mitochondriogenesis, given that PQQ can reduce synuclein fibril formation [161]
Halbirk M, Nrrelund H, Mller N, Holst JJ, Schmitz O, Nielsen R, Nielsen-Kudsk JE, Nielsen SS, Nielsen TT, Eiskjr H, et al: Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure
Insulin plays a crucial role in this process by directly impacting theca cells, increasing androgen secretion, stimulating the release of plasminogen activator inhibitor-1, and inhibiting plasmin production